Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

MYOS CORP Disrupts Advanced Nutrition Market with Launch of Cutting Edge "MYOS MD"


News provided by

MYOS Corp

May 09, 2024, 10:00 ET

Share this article

Share toX

Share this article

Share toX


Practitioner-Exclusive Product Line Created to Help Reduce Muscle Loss Associated with Age, Disuse, and Medical Treatment.

CEDAR KNOLLS, N.J., May 9, 2024 /PRNewswire-PRWeb/ -- MYOS CORP announced today the launch of MYOS MD, an advanced nutrition product line created to help reduce muscle loss associated with aging, disuse, and medical treatment. MYOS MD products are powered by the proprietary ingredient, Fortetropin®, an all-natural bioactive compound that has been shown in clinical studies to increase muscle growth, enhance rate of muscle protein synthesis, and lower levels of circulating myostatin.

Potential use cases for MYOS MD include:

"For several years we've felt very strongly about the potential for Fortetropin to play a big role in the medical nutrition space, and we're very excited to launch MYOS MD at this time," said MYOS CORP CEO Joe Mannello.

Post this
  • Limiting general muscle loss associated with aging
  • Limiting muscle loss from use of obesity medications to ensure healthy weight loss
  • Ensure effective muscle recovery for use pre/post orthopedic surgery

"For several years we've felt very strongly about the potential for Fortetropin to play a big role in the medical nutrition space, and we're very excited to launch MYOS MD at this time," said MYOS CORP CEO Joe Mannello. "Our product is backed by strong clinical science and meets a significant need in the marketplace. The doctors we've spoken to says they are in desperate need of a safe, effective, all-natural product that can assist in reducing muscle loss in their patients. We've gotten tremendous early reception from the medical world, and we're extremely excited about the growth potential of this business."

Age-related muscle loss is the gradual loss of muscle mass and function that occurs with aging. This condition affects approximately millions of adults over the age of 50, and it becomes worse with higher age. Age-related muscle loss can lead to decreased strength, mobility issues, and a higher risk of falls and fractures, significantly impacting an individual's independence and quality of life. It's caused by factors including reduced physical activity, changes in hormone levels, and decreased protein synthesis.

Dr. William Evans, a distinguished scholar at both the University of California-Berkley and Duke University, is an internationally recognized expert in muscle science research. His group's 2020 publication illuminated Fortetropin's potential, demonstrating how this singular proteo-lipid compound resulted in a substantial 18% elevation in the rate muscle protein synthesis in older adults. Notably, this enhancement occurred without any increase in physical activity on the part of the subjects, suggesting that Fortetropin has inherent anabolic properties, even for inactive individuals.

"Fortetropin has a robust effect on the rate of muscle protein synthesis in older men and women. It is rare for a nutrition product to show such a consistent and positive effect," Evans said of the results in 2020.

The results of the 2020 study provides implications for the challenge of preserving muscle mass during treatment with new weight loss products, as the adoption of such drugs has skyrocketed across the country. Use of products containing GLP-1 agonists (such as semaglutide) result in weight loss resulting from reduced appetite and decreased food intake. However, like many weight loss products, it can lead to muscle loss.

By combining a muscle health product like Fortetropin with a weight loss product, users should enjoy the weight loss benefits without the same degree of muscle depletion. Although there is currently no direct evidence linking Fortetropin's efficacy in counteracting muscle loss from weight loss products, experts such as Dr. Evans consider it a compelling avenue warranting deeper exploration.

"Stimulation of muscle protein synthesis, which Fortetropin has shown it provides, can have a positive effect of preserving muscle mass and increasing fat loss," said Dr. Evans. "The loss of muscle mass is common when individuals, especially as we age, lose weight rapidly."

Embracing this potential, MYOS envisions a synergistic approach, contemplating the pairing of Fortetropin with weight loss treatments. This could create an optimal balance, allowing individuals to reduce excess weight without compromising their precious lean muscle mass.

"Fortetropin's distinct advantage is its power to boost muscle growth and reduce muscle loss, all in a low calorie offering. It's an ideal choice for those aiming to shed weight without compromising muscle integrity," remarked MYOS CORP CEO Joe Mannello. "Metabolism is your body's mechanism of transforming intake into energy. A robust muscle mass increases your metabolic rate. However, when weight and muscle decrease, your metabolism decelerates, hindering your weight loss progress."

In addition to the aforementioned study at Cal Berkeley, there have been several other successful trials of Fortetropin showing its positive effect on muscle health. Clinical trials have shown:

  • Supplementation with Fortetropin lowered circulating myostatin in young males, favoring a positive net muscle protein balance supporting muscle growth or attenuating muscle loss.
  • In young men undergoing leg immobilization to create muscle disuse, supplementation with Fortetropin prevented a rise in circulating myostatin which may be important in mitigating disuse-induced atrophy and aiding recovery.
  • In a study with 100 dogs after TPLO surgery, Fortetropin prevented a rise in serum myostatin and limited the loss of muscle mass.

For more information, please visit www.myosmd.com.

About MYOS CORP

MYOS CORP is a Cedar Knolls, NJ-based medical nutrition company that develops products that improve muscle health in people and animals. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass, and reduce muscle atrophy. For more information, please visit www.myoscorp.com.

Media Contact

Dante Carnavale, MYOS Corp, 1 973-509-0555, [email protected], www.myoscorp.com

SOURCE MYOS Corp

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.